Mitoxantrone Injection is a chemotherapy drug and immunosuppressive agent belonging to the anthracenedione class. It is used in the treatment of certain cancers and autoimmune disorders due to its ability to interfere with DNA synthesis and suppress cell proliferation.

Here are the key details:

1. Composition and Form

• Active ingredient: Mitoxantrone hydrochloride.

• Supplied as a sterile solution for intravenous (IV) administration.

• Typically available in single-dose vials.

2. Mechanism of Action

• Intercalates into DNA, disrupting replication and transcription.

• Inhibits topoisomerase II, preventing DNA repair and causing strand breaks.

• Leads to cell cycle arrest and apoptosis, especially in rapidly dividing cells.

• Immunosuppressive effect reduces activity of T cells and B cells, which is useful in certain autoimmune conditions.

3. Indications

Oncology:

• Breast cancer (advanced or metastatic).

• Acute myeloid leukemia (AML).

• Prostate cancer (advanced, hormone-refractory).

• Sometimes used in other hematologic malignancies.

Autoimmune disorders:

• Multiple sclerosis (MS): reserved for rapidly worsening forms of relapsing or progressive MS when other treatments fail.

4. Administration

• Administered intravenously over several minutes (typically 5–15 minutes).

• Dose is based on body surface area and clinical protocol.

• Must be given under hospital supervision with monitoring for cardiac toxicity.

• Cumulative lifetime dose is limited due to risk of cardiomyopathy.

5. Side Effects

Common:

• Nausea, vomiting, diarrhea.

• Hair thinning or alopecia.

• Fatigue and malaise.

• Myelosuppression: leukopenia, anemia, thrombocytopenia.

Serious:

• Cardiotoxicity: risk of congestive heart failure increases with cumulative dose.

• Secondary leukemia (rare).

• Liver toxicity or elevated liver enzymes.

• Rare allergic reactions at the injection site or systemically.

Other:

• Blue-green discoloration of urine, sclera, and tears (temporary, harmless).

6. Contraindications

• Hypersensitivity to mitoxantrone or anthracenedione compounds.

• Severe bone marrow suppression.

• Active infections.

• Pregnancy and breastfeeding (teratogenic).

7. Precautions

• Monitor cardiac function with echocardiography or MUGA scan before and during therapy.

• Monitor blood counts, liver function, and renal function.

• Limit lifetime cumulative dose to reduce cardiac risk.

• Use caution in patients with pre-existing heart disease.

• Avoid live vaccines during treatment.

8. Storage

• Store refrigerated (2–8°C), protected from light.

• Use aseptically; discard any unused portion of single-dose vials.